1. Home
  2. CNVS vs RNTX Comparison

CNVS vs RNTX Comparison

Compare CNVS & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cineverse Corp.

CNVS

Cineverse Corp.

HOLD

Current Price

$2.32

Market Cap

46.9M

ML Signal

HOLD

RNTX

Rein Therapeutics Inc.

HOLD

Current Price

$1.49

Market Cap

38.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNVS
RNTX
Founded
2000
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Video Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
46.9M
38.9M
IPO Year
2003
N/A

Fundamental Metrics

Financial Performance
Metric
CNVS
RNTX
Price
$2.32
$1.49
Analyst Decision
Buy
Buy
Analyst Count
1
2
Target Price
$9.00
$10.00
AVG Volume (30 Days)
146.2K
234.4K
Earning Date
11-14-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$79,791,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$36.06
N/A
P/E Ratio
N/A
N/A
Revenue Growth
77.29
N/A
52 Week Low
$2.24
$1.04
52 Week High
$7.39
$3.50

Technical Indicators

Market Signals
Indicator
CNVS
RNTX
Relative Strength Index (RSI) 37.74 53.37
Support Level $2.40 $1.34
Resistance Level $2.51 $1.58
Average True Range (ATR) 0.15 0.10
MACD 0.02 0.01
Stochastic Oscillator 34.15 62.50

Price Performance

Historical Comparison
CNVS
RNTX

About CNVS Cineverse Corp.

Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.

About RNTX Rein Therapeutics Inc.

Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.

Share on Social Networks: